Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020;63(2):346-358.
doi: 10.1353/pbm.2020.0023.

Minimizing Risks Is Not Enough: The Relevance of Benefits to Protecting Research Participants

Minimizing Risks Is Not Enough: The Relevance of Benefits to Protecting Research Participants

David Wendler. Perspect Biol Med. 2020.

Abstract

Forty years ago, the Belmont Report counseled that a "systematic, nonarbitrary analysis of risks and benefits" is vital to ensuring the ethical appropriateness of research with human subjects. Since then, research ethics has devoted considerable attention to the first half of this advice, emphasizing the ethical importance of assessing and minimizing the risks of research with human subjects. Significantly less attention has been devoted to a systematic assessment of the potential benefits of research participation. To the extent that benefits for individual participants are considered at all, commentators tend to focus on their potential to undermine the goal of minimizing risks. A chance for clinical benefit may obscure the fact that research poses risks not present in clinical care, while an offer of financial compensation or ancillary care may induce individuals to accept risks that conflict with their long-term interests. This article argues that, while undoubtedly important, minimizing risks fails to offer sufficient protection for research participants, especially those who cannot consent, because it neither ensures that the risks of research are justified nor protects participants from exploitation. Belmont's advice to develop systematic and nonarbitrary ways to ensure that research participants receive appropriate benefits needs to be heeded as well.

PubMed Disclaimer

Similar articles

References

    1. Charlton V, et al. 2017. “Cost Effective but Unaffordable: An Emerging Challenge for Health Systems.” BMJ 356: j1402. - PubMed
    1. Dal-Re R, Rid A, and Wendler D. 2016. “The Potential Exploitation of Research Participants in High Income Countries Who Lack Access to Health Care.” Br J Clin Pharmacol 81: 857–64. - PMC - PubMed
    1. DiMasi J, Grabowski HG, and Hansen RW. 2016. “Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs.” J Health Econ 47: 20–33. - PubMed
    1. Goozner M, 2014. “Why Sovaldi Shouldn’t Cost $84,000.” Mod Healthc 44 (18): 26. - PubMed
    1. Gritsenko D, and Hughes G. 2015. “Ledipasvir/Sofosbuvir (Harvoni): Improving Options for Hepatitis C Virus Infection.” Pharmacol Therapeut 40 (4): 256–59. - PMC - PubMed

LinkOut - more resources